Gootz Thomas D
Pfizer Global Research and Development, Department of Antibiotics, Immunology and Cancer, MS 220-2301, Eastern Point Road, Groton, CT 06340, USA.
Biochem Pharmacol. 2006 Mar 30;71(7):1073-84. doi: 10.1016/j.bcp.2005.11.006. Epub 2005 Dec 13.
Gram-negative bacilli have become increasingly resistant to antibiotics over the past 2 decades due to selective pressure from the extensive use of antibiotics in the hospital and community. In addition, these bacteria have made optimum use of their innate genetic capabilities to extensively mutate structural and regulatory genes of antibiotic resistance factors, broadening their ability to modify or otherwise inactivate antibiotics in the cell. The great genetic plasticity of bacteria have permitted the transfer of resistance genes on plasmids and integrons between bacterial species allowing an unprecedented dissemination of genes leading to broad-spectrum resistance. As a result, many Gram-negative bacilli possess a complicated set of genes encoding efflux pumps, alterations in outer membrane lipopolysaccharides, regulation of porins and drug inactivating enzymes such as beta-lactamases, that diminish the clinical utility of today's antibiotics. The cross-species mobility of these resistance genes indicates that multidrug resistance will only increase in the future, impacting the efficacy of existing antimicrobials. This trend toward greater resistance comes at a time when very few new antibiotics have been identified capable of controlling such multi-antibiotic resistant pathogens. The continued dissemination of these resistance genes underscores the need for new classes of antibiotics that do not possess the liability of cross-resistance to existing classes of drugs and thereby having diminished potency against Gram-negative bacilli.
在过去20年里,由于医院和社区广泛使用抗生素带来的选择压力,革兰氏阴性杆菌对抗生素的耐药性日益增强。此外,这些细菌充分利用其固有的遗传能力,使抗生素耐药因子的结构和调控基因发生广泛突变,从而增强了它们在细胞内修饰抗生素或使其失活的能力。细菌巨大的遗传可塑性使得耐药基因能够通过质粒和整合子在不同细菌物种之间转移,导致基因前所未有的传播,进而产生广谱耐药性。结果,许多革兰氏阴性杆菌拥有一套复杂的基因,这些基因编码外排泵、外膜脂多糖的改变、孔蛋白的调控以及诸如β-内酰胺酶等药物失活酶,这些都降低了当今抗生素的临床效用。这些耐药基因的跨物种流动性表明,多重耐药性在未来只会增加,影响现有抗菌药物的疗效。这种耐药性增强的趋势出现之际,能够控制此类多重耐药病原体的新型抗生素极少被发现。这些耐药基因的持续传播凸显了对新型抗生素的需求,这类新型抗生素不应具有对现有药物类别产生交叉耐药性的缺点,从而不会降低对革兰氏阴性杆菌的效力。